08:27 AM EDT, 08/11/2025 (MT Newswires) -- Quantum BioPharma ( QNTM ) , up 4.2% in U.S. pre-market trade, on Monday said it has engaged a company to manufacture an oral drug formulation of its lead candidate, Lucid-MS.

The oral formulation of Lucid-MS will be used in Quantum's Phase 2 clinical trial, which will assess Lucid-MS's ability to help people with multiple sclerosis to regain mobility.

"We are pleased to announce that we have signed this agreement with a leading CDMO to develop and manufacture an oral formulation of Lucid-MS. This marks an important step in the clinical development of Lucid-MS as we prepare the Investigational New Drug (IND) application with the FDA and prepare for our upcoming Phase 2 trial of Lucid-21-302 in MS," said Dr. Andrzej Chruscinski, vice-president, scientific and clinical affairs.

Quantum shares are up US$1.22, to US$30.43, in New York trade.